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Leptin inhibits 4-aminopyridine–
and pentylenetetrazole-induced
seizures and AMPAR-mediated
synaptic transmission in rodents
Lin Xu,1,2 Nicholas Rensing,1,2 Xiao-Feng Yang,3 Hai Xia Zhang,1,2 Liu Lin Thio,1,2
Steven M. Rothman,3 Aryan E. Weisenfeld,4 Michael Wong,1,2 and Kelvin A. Yamada1,2
1Department of Neurology and 2Hope Center for Neurological Disorders, Washington University School of Medicine,
St. Louis, Missouri, USA. 3Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
4College of Arts and Sciences, Washington University, St. Louis, Missouri, USA.

Leptin is a hormone that reduces excitability in some hypothalamic neurons via leptin receptor activation of
the JAK2 and PI3K intracellular signaling pathways. We hypothesized that leptin receptor activation in other
neuronal subtypes would have anticonvulsant activity and that intranasal leptin delivery would be an effective
route of administration. We tested leptin’s anticonvulsant action in 2 rodent seizure models by directly injecting it into the cortex or by administering it intranasally. Focal seizures in rats were induced by neocortical
injections of 4-aminopyridine, an inhibitor of voltage-gated K+ channels. These seizures were briefer and less
frequent upon coinjection of 4-aminopyridine and leptin. In mice, intranasal administration of leptin produced elevated brain and serum leptin levels and delayed the onset of chemical convulsant pentylenetetrazoleinduced generalized convulsive seizures. Leptin also reduced neuronal spiking in an in vitro seizure model.
Leptin inhibited α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptor–mediated synaptic transmission in mouse hippocampal slices but failed to inhibit synaptic responses in slices from leptin
receptor–deficient db/db mice. JAK2 and PI3K antagonists prevented leptin inhibition of AMPAergic synaptic
transmission. We conclude that leptin receptor activation and JAK2/PI3K signaling may be novel targets for
anticonvulsant treatments. Intranasal leptin administration may have potential as an acute abortive treatment
for convulsive seizures in emergency situations.
Introduction
There is a pressing need for new anticonvulsants for children and
adults with medically refractory epilepsy. Neuropeptides such as
neuropeptide Y (NPY) and galanin are promising because they
have anticonvulsant effects in seizure models (1–5). However, the
potential of neuropeptides as anticonvulsants remains unexploited except for adrenocorticotropic hormone, an accepted treatment
for some childhood epilepsies (6). One factor limiting the clinical utility of neuropeptides such as NPY and galanin is that they
are not suited for peripheral administration because they do not
cross the blood-brain barrier. Thus, the peptide leptin may have
a clinical advantage because it has anticonvulsant properties and
crosses the blood-brain barrier via a transport system (7). Leptin
is potentially easy to administer because i.n. leptin administration
produces rapid, substantial increases in serum, cerebrospinal fluid,
and brain leptin levels (8, 9).
Nonstandard abbreviations used: ACSF, artificial cerebrospinal fluid; AMPA,
α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid; AMPAR, AMPA receptor;
4AP, 4-aminopyridine; BK channel, large-conductance calcium-activated neuronal
potassium channel; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; D-APV, d-2-amino5-phosphonovaleric acid; EPSC, excitatory postsynaptic current; fEPSP, field excitatory postsynaptic potential; KATP, ATP-sensitive K+; LPC, lysophosphatidylcholine; LTD,
long-term depression; LTP, long-term potentiation; NMDAR, N-methyl-d-aspartate
receptor; PTZ, pentylenetetrazole ; STP, short-term potentiation.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 118:272–280 (2008). doi:10.1172/JCI33009.
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Leptin receptor expression has been reported in the hippocampus and neocortex (10–12), but its functional role is poorly
understood. Recent studies in primary neuronal cultures and
hippocampal slices have characterized some of leptin’s anticonvulsant properties beyond its role in regulating energy homeostasis. In these studies leptin suppressed epileptiform-like bursting
and elevations in intracellular calcium under low extracellular
magnesium conditions by opening large-conductance calciumactivated neuronal potassium (BK) channels (11, 13, 14). Leptin
also induces long-term depression (LTD) under these conditions
(15). These results, combined with our and others’ observations
that ketogenic diets elevate serum leptin levels in rodents (16, 17),
motivated us to try to link leptin to the anticonvulsant effects
of ketogenic diets (i.e., high-fat, low-carbohydrate, and adequateprotein diets) sometimes used to treat intractable epilepsy (18).
We hypothesized that leptin may contribute to some of the anticonvulsant effects of ketogenic diets.
We recognize that leptin may be a proconvulsant. For example,
leptin increases spike frequency in a penicillin model of epileptiform activity (19). In addition, leptin enhances N-methyld-aspartate receptor (NMDAR) activity by activating PI3K and
MAPK (15, 20, 21). Leptin-induced activation of PI3K may
enhance AMPA receptor (AMPAR) synaptic transmission because
PI3K increases the surface expression of AMPARs (22, 23). Leptin
also converts short-term potentiation (STP) into long-term
potentiation (LTP) (21). Despite these effects, leptin produces a
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the cumulative seizure duration,
defined as the total duration of ictal
activity between 30 and 90 minutes
after 4AP injection, from 19 ± 9.3 minutes (n = 5) to 2.6 ± 1.7 minutes (n = 5;
P < 0.001, unpaired t test). Leptin did
not eliminate interictal spikes.
Intranasal leptin administration and
PTZ-induced seizures. PTZ, a GABA A
receptor antagonist, is a chemical convulsant that reliably produces generalized convulsive seizures (clonic-tonic)
when administered i.p. The rodent
PTZ seizure model is a standard animal
seizure model according to the NIH/
National Institute of Neurological Disorders and Stroke Anticonvulsant Drug
Development Program (25), possessing
a quantifiable seizure onset latency,
easily recognized behavioral seizures,
Figure 1
Leptin inhibits in vivo focal neocortical seizures in rats induced by 4AP injections into the left motor and predictive value for anticonvulsant
cortex. (A) Top trace: 15-minute EEG segment recorded from the frontal area ipsilateral to the efficacy against generalized seizures in
injection site 45 minutes after the injection of 12.5 nmol 4AP. Asterisks indicate 4 individual sei- humans. To determine if leptin inhibits
zures. Bottom trace: a 1-minute seizure at an expanded time base to illustrate the electrographic seizures in this model, we gave leptin
details of the seizure (underlined). (B) Top trace: 15-minute EEG segment recorded 45 minutes
i.n. to CD-1 mice 30 minutes before
after the injection of 12.5 nmol 4AP plus 39 pmol leptin shows 2 shorter, lower-amplitude seizures
(asterisks). Bottom trace: a 10-second seizure shown at an expanded time base (underlined). Note giving 75 mg/kg PTZ i.p. Rapid prothe different time calibration compared with A. (C) Location of the burr hole, injection site, and EEG gression from myoclonus to maximum
electrodes relative to standard landmarks. (D) Leptin reduced the frequency and duration of 4AP- severity generalized clonic-tonic seiinduced seizures. Seizure frequency (left) and duration (right) in rats injected with 12.5 nmol 4AP zures (and often death) in every mouse
alone (white bars; n = 5) or 12.5 nmol plus 39 pmol leptin (black bars; n = 5). Seizure frequency and within 10 minutes obviated the need
duration for each rat were determined from the 60 minutes of EEG recordings collected between to grade seizure severity in this model.
30 and 90 minutes after 4AP injection. *P < 0.02 for frequency vs. 4AP alone and *P < 0.001 for
A leptin dose of 800 μg/kg more than
duration vs. 4AP alone (unpaired t test).
doubled the seizure latency compared
with control (Figure 2A). Leptin doses
of 8 and 80 μg/kg also increased seizure
small decrease in basal AMPAR-mediated synaptic currents (21). latency, but the differences were not statistically significant (data
Whether PI3K activation underlies this effect is unknown.
not shown). Leptin was not a proconvulsant at the 3 doses used.
In the experiments described below, we characterize the effects
Brain and serum leptin levels after i.n. leptin administration. As
of leptin on neuronal excitability. First, we determined whether described previously (8, 9), we observed that serum and brain
leptin is an anticonvulsant in an in vivo rat model of focal neo- leptin levels increased 30 minutes after i.n. leptin administration.
cortical seizures induced by 4-aminopyridine (4AP) (24). Second, Significant increases in serum and brain leptin levels occurred 30
we determined whether i.n. leptin administration inhibits gen- minutes after administration of 800 μg/kg leptin i.n. (Figure 2, B
eralized convulsions induced by pentylenetetrazole (PTZ) and and C). All brains of mice that received 800 μg/kg leptin showed
increases brain leptin levels. Finally, we investigated whether leptin leptin levels above 20 pg/mg protein, which we determined to be
inhibits AMPAR-mediated synaptic transmission in hippocampal the lowest level of detection with this assay. Leptin doses of 8 and
slices via a leptin receptor–mediated mechanism involving JAK 80 μg/kg produced smaller increases in serum and brain leptin levand PI3K signaling.
els; at both doses, brain leptin was near the detection threshold of
20 pg/mg protein. All vehicle-treated mice had brain leptin levels
Results
below 20 pg/mg protein.
Leptin shortens and reduces 4AP-induced neocortical seizure in rats.
Leptin inhibits synaptic responses in mouse hippocampal slices. In
Direct cortical injection of 12.5 nmol 4AP alone in rats consis- hippocampal slices, leptin enhances NMDAR-mediated responstently induced recurrent seizures typically lasting about 1 minute, es and converts STP to LTP (21). This effect was unlikely to have
within 30 minutes of injection (24) (Figure 1). 4AP, a nonspecific accounted for our observation that leptin reduces 4AP-induced
inhibitor of voltage-gated K+ channels, induced seizures that were seizures. However, Shanley et al. (21) also observed modest,
easy to identify electrographically by their discrete onset, stereo- reversible inhibition of AMPAR-mediated excitatory postsyntypically evolving amplitude and frequency features, and abrupt aptic currents (EPSCs) without changes in the cell input resiscessation (Figure 1A). Electrographic seizures in rats coinjected tance, which raises the possibility that AMPAR inhibition could
with 12.5 nmol 4AP + 39 pmol leptin were of lower amplitude partially explain leptin’s anticonvulsant action. The absence of
and noticeably briefer and less frequent than in rats injected with reduced input resistance would argue against increased tonic
12.5 nmol 4AP plus vehicle (Figure 1, B and D). Leptin decreased activity of ion channels such as BK or ATP-sensitive K + (KATP)
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Figure 2
Intranasal leptin inhibits in vivo PTZ-induced generalized convulsive
seizures and elevates serum and brain leptin levels in mice. (A) In 6- to
8-week-old CD-1 mice, 800 μg/kg leptin (n = 15) given i.n. 30 minutes
before the i.p. injection of 75 mg/kg PTZ significantly increased the
latency to behaviorally assessed generalized clonic-tonic seizures.
*P < 0.002 compared with mice that received vehicle (n = 16). (B) Cortex leptin per milligram of cortex protein (*P < 0.001). (C) Serum leptin
concentrations increased significantly (*P < 0.0001) after 800 μg/kg
leptin i.n. compared with vehicle. The Mann-Whitney U test was used
for the statistical analysis.

channels. Therefore, we examined the effect of leptin on CA1
stratum radiatum field excitatory postsynaptic potentials
(fEPSPs) evoked by Schaffer collateral stimulation in
hippocampal slices. Fifteen minutes after bath-applied 0.6 nM
leptin, a reversible reduction of 81% ± 6% (n = 7 slices, 6 mice)
occurred in the slope of the fEPSP (Figure 3, A and B). Leptin
produced a U-shaped, concentration-dependent inhibition of
the fEPSP slope; 50 nM leptin produced only a 4% ± 7% reduction in the slope (n = 6 slices, 2 mice) (Figure 3C).
Leptin selectively inhibits the AMPAR component of the fEPSP and
increases paired pulse facilitation. To evaluate whether leptin differentially inhibited AMPARs and NMDARs, we pharmacologically
isolated these components of the fEPSP and examined leptin’s
effects. The CA1 fEPSP slope in nominally Mg2+-free (no added)
artificial cerebrospinal fluid (ACSF) was 97.0% ± 4% (n = 4 slices, 1
mouse) of the baseline response obtained in standard ACSF. In the

same slices, the fEPSP slope was reduced to 26% ± 6% of the baseline response after the addition of 10 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) to the ACSF to block the AMPAR-mediated
component of the fEPSP; the fEPSP slope was further reduced to
5% ± 2% of the baseline response after application of ACSF with
both 10 μM CNQX and 50 μM d-2-amino-5-phosphonovaleric
acid (D-APV, an NMDAR antagonist). In ACSF with 50 μM D-APV,
0.6 nM leptin inhibited the isolated AMPAR component of the
fEPSP; the fEPSP slope after 30 minutes of leptin application
was 26% ± 2% of baseline (n = 4 slices, 2 mice; Figure 4A). In Mg2+free ACSF with 10 μM CNQX, leptin did not affect the isolated
NMDAR component of the fEPSP (Figure 4B).
The selective inhibition of the AMPAR component of the fEPSP
generally supports a postsynaptic mechanism. To further distinguish between a pre- and postsynaptic site of action, we examined
the effect of leptin on paired pulse facilitation. We compared the
paired pulse ratio (P2/P1, where P1 is the slope of the first fEPSP
and P2 is the slope of the second fEPSP) at baseline and after applying 0.6 nM leptin for 20 minutes. Leptin reduced the slope of both
fEPSPs in a pair (Figure 4C, arrows) and slightly but significantly
increased the paired pulse ratio (Figure 4D), which suggested an
additional presynaptic inhibitory mechanism.

Figure 3
Leptin inhibits CA1 fEPSPs in mouse hippocampal slices. (A) Representative tracings of Schaffer collateral evoked fEPSPs recorded
in CA1 at baseline during perfusion of ACSF (Baseline), after a 20minute perfusion with 0.6 nM leptin (Leptin), and after a 30-minute
washout with ACSF (Recovery). Calibration: 2 ms, 0.1 mV. (B) Time
course of the fEPSP slope demonstrates the inhibition of fEPSP during
a 20-minute application of 0.6 nM leptin (indicated by the bar), which
almost completely recovers after a 30-minute washout with ACSF
(n = 7 slices, 6 mice). fEPSP slopes at each time point were normalized to the slope of the baseline fEPSPs, which is indicated by the
dotted line. Only every third point is shown for clarity. (C) U-shaped
concentration-response curve of leptin inhibition of the fEPSP slope
demonstrates maximal inhibition at 0.6 nM and minimal inhibition at
0.006 and 50 nM leptin (n = 6 slices, 2 mice).
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dione (NBQX) — a selective AMPAR antagonist — was
97% ± 3.2% of the control (n = 5 cells). Together these
results suggest that leptin inhibits AMPAR-mediated
synaptic transmission pre- and postsynaptically.
Leptin inhibits low magnesium–induced spiking in cultured
hippocampal neurons. To determine whether leptin reduces
neuronal hyperexcitability at concentrations comparable
with those that inhibit AMPAergic EPSPs and EPSCs in slices, we examined the effect of leptin on the bursts of action
potentials induced in cultured hippocampal neurons by
nominally Mg2+-free extracellular solution (26, 27). Cultured hippocampal neurons generally fire isolated action
potentials when Mg2+ is present in the extracellular solution. When the extracellular solution contains no added
Mg2+, the neurons fire bursts of action potentials superimposed on a depolarizing wave that resembles a paroxysmal
depolarizing shift (Figure 6A). Leptin decreased action
potential bursting (Figure 6B, 1 nM leptin), which partially reverted to baseline spike frequency after leptin washout (Figure 6C). Cumulative data show that 1 and 10 nM
Figure 4
leptin, but not 0.1 nM leptin, significantly decreased
Leptin selectively inhibits the AMPAR-mediated component of the CA1 field action potential bursting on the basis of a comparison of
excitatory postsynaptic potentials (fEPSPs) in mouse hippocampal slices. (A) spike frequency in the same neuron before and after leptin
Leptin inhibited the AMPAR component of the CA1 fEPSP. Time course of the
application (Figure 6D). Thus, leptin decreases neuronal
fEPSP slope for the AMPAR component after bath-applied 0.6 nM leptin as
hyperexcitability in cultured hippocampal neurons in the
indicated by the bar (n = 4 slices, 2 mice). The AMPAR component was isolated
by adding the N-methyl-d-aspartate (NMDA) antagonist D-APV (50 μM) as indi- same concentration range that decreases AMPAR-medicated by the bar. (B) In contrast, leptin did not inhibit the NMDAR component ated EPSCs in hippocampal slices.
In separate experiments we examined whether leptin
of the CA1 fEPSP. Time course of the fEPSP slope for the NMDA component
after bath-applied 0.6 nM leptin as indicated by the bar (n = 6 slices, 4 mice). alters neuronal input resistance or action potential propThe NMDAR component was isolated by adding the AMPAR antagonist CNQX erties. We used cultured hippocampal neurons because
(10 μM) in Mg2+-free ACSF. Data in A and B were analyzed as in Figure 3B. The they are more compact electrically, which makes leptinbars indicate when Mg2+-free ACSF and leptin were applied. (C and D) Leptin
induced changes in input resistance easier to detect.
enhances paired-pulse facilitation. (C) Superimposed representative pairs of
CA1 fEPSPs from the same slice demonstrate fEPSP inhibition and increased Leptin concentrations of 0.1, 1, and 10 nM had no effect
paired pulse facilitation in 0.6 nM leptin (arrows). Interstimulus interval: 25 ms; on neuronal input resistance or action potential propercalibration: 4 ms, 0.2 mV. (D) Cumulative data from 5 slices (5 mice) comparing ties (threshold, amplitude, or duration; see Supplemental
the paired pulse facilitation ratio (PPF = P2/P1, where P1 is the slope of the first Table 1; supplemental material available online with this
fEPSP and P2 is the slope of the second fEPSP) before and after the applica- article; doi:10.1172/JCI33009DS1).
tion of 0.6 nM leptin for 20 minutes (*P < 0.02, paired t test).
JAK and PI3K inhibitors prevent leptin inhibition of fEPSP.
Leptin receptors are class I cytokine receptors that signal via association with JAKs. When leptin binds to the
Given that the above results do not definitively support a pre- long form of the leptin receptor, Ob-Rb, JAK2 is activated and
synaptic mechanism, we used whole-cell voltage clamp record- both proteins are subsequently phosphorylated, which results in
ings from CA1 pyramidal neurons to examine the effect of the recruitment and activation of downstream signaling pathleptin on AMPAR- and NMDAR-mediated EPSCs. Leptin inhib- ways in hematopoietic, adipocyte, pancreatic, and muscle cells
ited AMPAR-mediated EPSCs and fEPSPs in a similar manner, (28, 29). Evidence indicates that JAK/PI3K signaling is imporexcept that only partial recovery occurred with washout (Figure tant in neurons (30–32), and leptin-mediated effects in neurons
5A). Leptin at 0.6 nM reduced the amplitude of AMPAR EPSCs have been shown to be inhibited by JAK inhibitors (33–35) and
recorded at –70 mV by 56% ± 20% (n = 9); a lower and a higher PI3K inhibitors (11, 36).
concentration of leptin produced no change (Figure 5B). In 2
Therefore, we examined whether JAK and PI3K inhibitors
other cells, 0.6 nM leptin did not inhibit the AMPAR-mediated prevent leptin from decreasing CA1 fEPSPs. After baseline
EPSC; these cells were not included in the amplitude analysis. EPSP recordings were obtained, application of the JAK2 inhibiLeptin produced a larger increase in paired-pulse facilitation of tor AG490 alone (20 μM; 45–60 minutes) had no effect on the
AMPAR-mediated EPSCs than in fEPSPs (Figure 5C). In 8 of 11 fEPSP slope (data not shown). However, preincubating slices
cells, leptin also significantly lengthened the EPSC latency from with AG490 for at least 3 hours prevented 0.6 nM leptin from
3.2 ± 0.5 to 4.3 ± 1.0 ms (P < 0.02, paired t test), with partial recovery inhibiting CA1 fEPSPs (Figure 7A). We also used 2 structurally
to baseline on leptin washout. Leptin clearly inhibited the EPSC unrelated PI3K inhibitors, LY294002 and wortmannin, to invesin 2 of the 3 cells that exhibited no change in EPSC latency. The tigate whether PI3K activation is necessary for leptin’s effect.
mean amplitude of NMDAR-mediated EPSCs recorded at +20 mV Application of LY294002 (16 μM) or wortmannin (50 nM)
in ACSF containing 2 mM CaCl 2, 1 mM MgCl 2, and 10 μM alone had no effect on baseline fEPSP slope (data not shown).
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3- Preincubation with either agent for at least 3 hours completely
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Figure 5
Leptin inhibits AMPAR-mediated EPSCs obtained from voltageclamped CA1 pyramidal neurons in mouse hippocampal slices. (A)
Representative tracings of Schaffer collateral evoked whole-cell
EPSCs recorded from a voltage-clamped CA1 neuron at –70 mV at
baseline during perfusion of ACSF containing 2 mM CaCl2 and 1 mM
MgCl2 (Baseline), after a 10-minute perfusion with 0.6 nM leptin
(Leptin), and after a 20-minute washout with ACSF (Recovery). Calibration: 5 ms, 25 pA. (B) Leptin inhibited AMPAR-mediated EPSCs with a
U-shaped dose-response relation. Peak amplitudes of AMPAR-mediated EPSCs after a 10-minute perfusion with various leptin concentrations expressed as a percentage of the peak amplitude of the baseline
EPSC (n = 5–9 cells). *P < 0.001 for 0.6 vs. 0.06 nM and *P < 0.01
for 0.6 vs. 50 nM leptin (ANOVA followed by Tukey-Kramer’s test for
multiple comparisons). (C) Leptin-enhanced paired pulse facilitation.
The paired-pulse ratio was calculated as in Figure 4 by using peak
amplitudes of pairs of EPSCs evoked with an interstimulus interval of
25 milliseconds in 0.6 nM leptin. n = 8 cells, *P < 0.02 (paired t test).

from db/db mice, leptin did not alter CA1 fEPSP slopes; the slopes
were 93% ± 12% (n = 10 slices, 3 mice) of baseline after application
of 0.6 nM leptin for 30 minutes. This result indicates that Ob-Rb
activation is necessary for leptin to inhibit AMPAR-mediated CA1
hippocampal synaptic responses.

prevented leptin-induced inhibition of fEPSPs (Figure 7, B and
C). These data indicate that leptin-induced inhibition of CA1
hippocampal AMPAR synaptic responses requires activation of
the JAK2/PI3K signaling pathway.
Effects of leptin in db/db mice. Leptin acts systemically to orchestrate complex biological effects through its specific cellular receptor. As mentioned above, the long form of Ob-Rb is capable of
full signal transduction. To address whether leptin inhibition
of AMPAR-mediated synaptic responses requires leptin receptor
activation, we compared the effects of leptin on CA1 fEPSPs in
hippocampal slices from db/db mice, which are Ob-Rb deficient
(37), and from wild-type C57BLKS/J mice, the background strain
of db/db mice. In slices from C57BLKS/J mice, leptin inhibited
synaptic responses as observed in CD-1 mice; CA1 fEPSP slopes
were 34% ± 3 % (n = 6 slices, 3 mice) of baseline after perfusion
with 0.6 nM leptin for 30 minutes (Figure 8). However, in slices

Discussion
Leptin is an anticonvulsant in a focal and a generalized seizure model.
The ketogenic diet, an effective anticonvulsant therapy, elevates
serum leptin levels in rodents (16, 17). Leptin reduces neuronal
excitability and epileptiform activity in vitro (11), and Durakoglugil et al. (15) postulated, based on leptin’s actions in vitro, that
leptin is an endogenous anticonvulsant. Accordingly, we found
that leptin decreased the frequency and duration of 4AP-induced
focal neocortical seizures in rats. In addition, i.n. administered
leptin (800 μg/kg) elevated brain leptin and increased the latency
of PTZ-induced generalized seizures. Two lower doses of leptin (8
and 80 μg/kg) produced a trend toward increased PTZ-induced
seizure latency without a consistent elevation in brain leptin with
our assay. We speculate that the lower leptin doses produce higher

Figure 6
Leptin inhibits low magnesium–induced spiking in cultured mouse
hippocampal neurons. (A) Whole-cell patch recordings from cultured
hippocampal neurons in current clamp configuration spontaneously
fire action potentials in nominally magnesium-free external solution.
Baseline membrane potential: –57 mV. Calibration for A1–A3: 10 s,
30 mV. (B) Leptin (1 nM) reduces action potential firing frequency
by 30%–40%. (C) Action potential firing recovers close to baseline
frequency after leptin washout. (D) Cumulative data comparing spike
frequency in low magnesium before (filled squares) and after (open
squares) application of different leptin concentrations. Each filled
and open symbol connected by a line represents 1 cell and its firing
frequency before and after leptin. Therefore, each line represents 1
matched data pair; some data points are superimposed on each other.
The mean ± SD values are presented beside each data set with a
larger symbol. A significant reduction in spike frequency was produced
by 1.0 nM (n = 13 cells) and 10 nM (n = 11 cells), but not by 0.1 nM
(n = 12 cells) leptin (paired t test).
276
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Figure 7
Leptin inhibition of CA1 fEPSPs in mouse hippocampal slices depends
on JAK2 and PI3K activation. The JAK2 inhibitor AG490 and the PI3K
inhibitors LY294002 and wortmannin prevented leptin-induced fEPSP
inhibition. Time course of CA1 fEPSP slopes after the application of
0.6 nM leptin as indicated by the bar in slices pretreated for at least
3 hours in 20 μM AG490 (n = 5 slices, 3 mice) (A), 16 μM LY294002
(n = 7 slices, 2 mice) (B), or 50 nM wortmannin (n = 6 slices, 2 mice)
(C). Data were analyzed as in Figure 3B.

than basal brain leptin levels, which are below the detection level
of the assay, yet impart some anticonvulsant effect not robust
enough to produce a statistically significant group effect. We
conclude that leptin is an anticonvulsant against acute seizures
induced by 2 convulsants with different mechanisms of action
and against both focal and generalized seizures in vivo. Whether
leptin is effective against sporadic seizures in chronic epilepsy is
unclear and requires further study. It is possible that leptin counters acute emergent seizures but is not an effective anticonvulsant when administered chronically. Importantly, we found no
evidence that leptin has proconvulsant effects, despite observations that raise the possibility that leptin might increase neuronal
excitability and worsen seizures (19, 21).
Leptin inhibits AMPAergic synaptic responses and low magnesium–
induced spiking. We found that a narrow range of leptin concentrations inhibit AMPAR-mediated synaptic responses. A maximally
effective leptin concentration of 0.6 nM inhibited AMPAR-mediated CA1 fEPSP by 80% and CA1 EPSCs by 60%; lower and higher
concentrations produced less inhibition. Results similar to ours
were reported by Shanley et al. (21), who found that 50 nM leptin
inhibits AMPAR-mediated CA1 EPSCs by 20%; however, they
did not report the effects of lower leptin concentrations. Other
effects of leptin, such as those on the modulation of CA1 LTP
in hippocampal slices (38, 39), the medial perforant path LTP in
vivo (40), and intracellular Ca2+ (11, 39), also showed a U-shaped
dependence on leptin concentration. These results suggest that
the effects of leptin are highly regulated and complex.

Our results did not allow us to determine which of leptin’s many
potentially anticonvulsant effects contribute to its anticonvulsant
effect in vivo. In addition to the inhibition of AMPAR-mediated
synaptic transmission, leptin’s anticonvulsant effect may result
from NMDAR inhibition (39) or BK channel activation (11, 13, 36).
Our results are consistent with those of a model in which the inhibition of AMPAR-mediated synaptic transmission contributes to
leptin’s anticonvulsant effect at low (nanomolar) concentrations,
and other mechanisms contribute at higher concentrations. We
found that low (nanomolar) leptin concentrations inhibit experimentally induced bursting in cultured neurons (Figure 6). This
result is consistent with the inhibition of AMPAR-mediated synaptic transmission contributing to leptin’s anticonvulsant effect.
However, we expect leptin to have a narrow therapeutic range as
an anticonvulsant in vivo if the inhibition of AMPAR-mediated
synaptic transmission were its only anticonvulsant mechanism
based on the U-shape concentration response curve. However,
leptin does not appear to have a narrow therapeutic range as an
anticonvulsant in vivo. Thus, we predict that other mechanisms,
such as the induction of LTD (15), the activation of BK (11, 13,
36), and the activation of KATP channels (41), may contribute to
leptin’s anticonvulsant effects at higher leptin doses. These effects
of leptin require 100-fold higher leptin concentrations than needed to inhibit AMPAR-mediated synaptic transmission.
Differential effects of leptin on AMPAR and NMDAR responses.
Leptin can modulate AMPAR-mediated synaptic responses by
altering NMDAR-dependent forms of long-term synaptic plasticity. In the hippocampus, leptin enhances LTP (38–40), converts STP into LTP (21), and induces a novel form of LTD (15).

Figure 8
Leptin inhibition of CA1 field excitatory postsynaptic potentials
(fEPSPs) in mouse hippocampal slices depends on the long form of
the leptin receptor. Leptin did not inhibit fEPSPs in hippocampal slices
obtained from leptin receptor (Ob-Rb)–deficient db/db mice, but did
inhibit fEPSPs in slices from wild-type C57BLKS/J mice. The time
course of CA1 fEPSPs after the application of 0.6 nM leptin is indicated
by the bar for slices from db/db mice (n = 6 slices, 3 mice) (triangles)
and C57BLKS/J mice (n = 10 slices, 3 mice) (squares). Data were
analyzed as in Figure 3B.
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The leptin-induced inhibition of AMPAergic synaptic responses
reported herein is not a form of NMDAR-dependent long-term
synaptic plasticity because the inhibition reverses on leptin
removal. The inhibition we observed occurred independently
of NMDAR activation because it occurred when Mg2+ or D-APV
blocked NMDARs. Moreover, to inhibit AMPAergic synaptic
responses, we used nearly 100-fold lower leptin concentrations
than required to enhance NMDAR responses or modulate longterm synaptic plasticity (15, 21).
The increase in paired-pulse facilitation of CA1 fEPSPs and
EPSCs suggests that leptin inhibits AMPAR-mediated synaptic transmission presynaptically. Consistent with a presynaptic
effect, 0.1 nM leptin, a concentration that inhibits CA1 fEPSPs,
did not alter spontaneous miniature EPSC amplitudes in CA1
neurons (39). A potential presynaptic mechanism based on a
well-established leptin effect is BK channel activation (11, 13, 36).
Although BK channel activation contributes to action potential
repolarization in CA3 pyramidal neurons, BK channel activation
may only alter transmitter release at CA3-CA1 synapses under
hyperexcitable conditions (42, 43). In addition, leptin activation
of BK channels requires much higher leptin concentrations than
needed to inhibit AMPAR-mediated synaptic transmission. Thus,
BK channel activation may contribute to the anticonvulsant
effect of leptin in vivo, but it may not be the primary mechanism
by which leptin inhibits AMPAR-mediated synaptic transmission
under normal conditions.
We also observed that leptin selectively inhibited the AMPAR
component of the CA1 fEPSP and EPSC. A differential effect on
the AMPA or NMDA component of an EPSP or EPSC is evidence
of a postsynaptic effect (44, 45). Despite the marked differences in
NMDAR and AMPAR sensitivity to glutamate, presynaptic manipulations do not selectively affect one component (45). A postsynaptic effect is consistent with the tendency for 0.1 nM leptin to
decrease depolarizations induced by iontophoretic applications
of quisqualate, an AMPAR agonist, in CA1 neurons (39). Thus,
our results suggest that leptin inhibits AMPAR-mediated synaptic
transmission pre- and postsynaptically.
Leptin receptor activation of the JAK2/PI3K pathway inhibits AMPARmediated fEPSPs. Our results with 1 JAK2 inhibitor and 2 PI3K
inhibitors and db/db mice suggest that leptin inhibits AMPAergic
synaptic responses by binding to its receptor and activating the
JAK2/PI3K pathway. We examined this pathway because leptin
enhances NMDAR-mediated responses (21) and activates BK and
KATP channels (13) via this pathway. We also examined this pathway
because AMPARs complex with PI3K (22). Consequently, our results
raise the possibility of a postsynaptic JAK2/PI3K-dependent mechanism for the inhibition of AMPAR-mediated synaptic transmission
by leptin. However, PI3K activation causes AMPAR insertion (22,
23), which should result in enhanced synaptic transmission. Such a
mechanism would account for some leptin concentrations enhancing long-term synaptic plasticity at excitatory synapses (21, 38–40).
PI3K also regulates endocytosis (46, 47) and thereby may modulate
AMPAR internalization (48). We speculate that different concentrations of leptin can produce opposing effects on AMPAR-mediated synaptic responses via a common PI3K signaling pathway (22)
by differently modulating the sources and subcellular locations of
leptin-dependent intracellular calcium changes.
Conclusion. Our data support the hypothesis that leptin is an
anticonvulsant in vivo because the leptin receptor activates the
JAK2/PI3K pathway and inhibits AMPAR-mediated synaptic
278

transmission by a pre- and postsynaptic mechanism. Leptin’s
potential as a clinically useful anticonvulsant is enhanced because
i.n. administration increases brain leptin levels, and leptin inhibits
focal and generalized seizures (8). Although other anticonvulsants
inhibit glutamatergic transmission, leptin may afford a broader
range of treatment strategies because it is a peptide. For example,
gene delivery strategies (49) might enable inducible leptin expression in an epileptogenic cortical region refractory to conventional
anticonvulsants and not amenable to surgical treatment. Dietary
modifications can increase systemic leptin levels (16, 17), and its
transport into the brain may be enhanced by manipulating its
endogenous transporters (7). Our results highlight leptin’s potential for treating epilepsy by targeting brain leptin receptors and
underscore the importance of understanding its regulation and
physiological actions in the CNS.
Methods
Animals. Male Sprague-Dawley rats, Swiss-Webster mice, and CD-1 mice
were purchased from Charles River Laboratories. Male db/db (Stock
000642) and C57BLKS/J (Stock 000662) mice were purchased from Jackson Laboratory. Animal care and experimentation methods conformed to
the Public Health Service Guide for the Care and Use of Laboratory Animals and the American Veterinary Medical Association Panel on Euthanasia Guidelines and were approved by the Washington University School of
Medicine Animal Studies Committee.
Tissue preparation for electrophysiology. Primary dissociated hippocampal
cultures were prepared from E15 Swiss-Webster mouse embryos on glass
coverslips with preapplied glial feeder layers as described previously (50).
Cells were used for patch-clamp recordings between 9 and 14 days in vitro.
Hippocampal slices were prepared as described previously (51) from 6- to
8-week-old mice for extracellular recordings and from 3-week-old mice for
whole-cell recording. Mice were killed under halothane at approximately
the same time each morning because of leptin’s diurnal variation. Brains
were rapidly removed; placed in ice-cold ACSF consisting of 124 mM NaCl,
5 mM KCl, 2.5 mM CaCl2, 1.3 mM MgCl2, 1.3 mM NaH2PO4, 22 mM
NaHCO3, and 10 mM glucose; and saturated with 95% O2/5% CO2 to a
pH of 7.4. Transverse hippocampal slices (400 μm) were prepared with a
vibratome and incubated for at least 1 hour in ACSF at room temperature
before the recording experiments were conducted.
Materials. Recombinant mouse leptin, d-APV, and the disodium salt of
CNQX were purchased from Sigma-Aldrich. AG490, LY294002, and wortmannin were obtained from Calbiochem. Leptin stock solution consisted
of 1 mg lyophilized leptin solubilized in 0.5 ml 15 mM HCl followed by
the addition of 0.3 ml 7.5 mM NaOH to raise the pH to about 5.2. The
resulting stock solution was diluted in ACSF for cortical injection or in vitro
electrophysiology experiments. To enhance CNS absorption after i.n. leptin
administration (9), 1 mg lysophosphatidylcholine (LPC; Sigma-Aldrich)
was dissolved in 0.2 ml 0.9% saline and mixed with 0.8 ml of the leptin stock
solution to a final concentration of 1 mg/ml leptin and 0.1% LPC.
Leptin assay. Serum and brain leptin levels were measured with the use
of a commercial mouse ELISA kit (EZML-82K; Linco Research/Millipore
Corp.). Leptin standards containing concentrations below 0.1 ng/ml
were indistinguishable from the blanks, which indicated that the lower
limit of detection is 0.1 ng/ml leptin. Therefore, all samples with readings below the average 3 SDs for a blank were considered to have an
undetectable leptin level, i.e., less than 0.1 ng/ml leptin. Brain or serum
samples with higher than the maximum quantifiable level of leptin were
diluted with assay buffer to obtain measurements within the range of
the leptin standards in the kit, and values were calculated using the
appropriate dilution factor.
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Mice were deeply anesthetized, and then a thoracotomy was performed
to expose the heart. Blood was obtained by right atrium puncture and centrifuged at 15,900 g for 15 minutes at 4°C. Next, intracardiac perfusion was
performed via the left ventricle using cold (0–4°C) PBS for 5–7 minutes,
which was followed by brain removal. Pieces of frontal-parietal cerebral
cortex and serum samples were immediately frozen on dry ice and stored at
–80°C until processed. Brain leptin levels were measured in some animals
that received PTZ. These animals were not perfused, but control experiments showed that the leptin from the blood remaining in the nonperfused brain did not produce detectable brain leptin levels.
The leptin ELISA was performed on brain and serum samples according to the manufacturer’s instructions. Brain levels were measured in
samples (~30–50 mg) prepared by mixing with 10 ml lysis buffer per 1 mg
tissue. Lysis buffer consisted of 160 mM KCl, 25 mM HEPES, and 1%
Triton X-100. Samples were sonicated and mixed on a micro-rotator for
1 hour and then centrifuged for 20 minutes at 4°C at 15,900 g. The
supernatant was stored at –80°C until analyzed. For leptin measurements, different dilutions of supernatant were made with assay buffer
from the kit. Leptin levels in these samples of brain tissue were normalized to protein levels, which were determined using a commercially
available kit (Micro BCA Protein Assay Kit; Pierce Biotechnology Inc.).
All measurements were done in triplicate.
Neocortical seizure model. Four- to six-week-old male Sprague-Dawley rats
were anesthetized with halothane (4%) and then placed on a stereotaxic
frame (David Kopf Instruments). A burr hole was drilled over the left hemisphere at a site 2 mm anterior to the bregma and 2.5 mm lateral to midline
with a dental drill. After surgery, halothane was reduced to 1%–2% and 1 ml
ACSF containing 12.5 mM 4AP (12.5 nmol) was injected from a glass
micropipette (tip diameter: 100 μm) into the motor cortex 0.5 mm deep to
the cortical surface with a commercial injector (Nanoject; Drummond Scientific). This model produces frequent repetitive seizures narrowly localized to the site of injection (24). Leptin-treated rats were injected with 1 ml
ACSF containing 12.5 mM 4AP and 39 μM leptin (39 pmol). Two screw
electrodes were placed symmetrically over each hemisphere and differentially recorded the EEG in a referential montage with the use of standard
AC EEG amplifiers (Grass-Telefactor). The EEG was digitized (200 Hz) and
stored with the use of PC-based commercial hardware (Digidata and Axoscope; Axon Instruments). EEG recordings started 15 minutes before and
ended 90 minutes after the 4AP injection. The EEG was visually analyzed
by a reviewer blinded to the experimental protocol to determine the number of seizures in a record and seizure duration. A seizure was defined as
a discrete electrographic event with an onset consisting of low-amplitude,
high-frequency discharge followed by an evolving rhythmic, repetitive,
high-amplitude discharge with a distinct termination.
PTZ generalized seizure model. Six- to eight-week-old male CD-1 mice were
divided into a vehicle-treated control group and a leptin-treated group. A
20-mg/ml PTZ stock was made by using sterile 0.9% saline, and each mouse
received 75 mg/kg PTZ via i.p. injection. Leptin-treated rats received 8, 80,
or 800 μg/kg in 0.1% LPC i.n. 30 minutes before PTZ administration. Control mice received LPC vehicle without i.n. leptin. All mice, regardless of
the leptin dose administered, received a total volume of 20 μl. An observer,
blinded to the treatment administered, measured the latency to the onset
of the first generalized convulsive seizure as assessed behaviorally.
1. Vezzani, A., Sperk, G., and Colmers, W.F. 1999.
Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci.
22:25–30.
2. Dube, C., Brunson, K.L., Eghbal-Ahmadi, M., Gonzalez-Vega, R., and Baram, T.Z. 2005. Endogenous
neuropeptide Y prevents recurrence of experimental febrile seizures by increasing seizure threshold.

Electrophysiology experiments. Hippocampal slices were transferred to a
submerged recording chamber (Warner Instruments) and perfused continuously at a rate of 3 ml/min with ACSF (see above) at 30°C. Glass
electrodes filled with 2 M NaCl (resistance: 3–5 MΩ) were used to record
fEPSPs from CA1 stratum radiatum. EPSPs were evoked via stimulation
of the Schaffer collateral pathway through a bipolar electrode (David
Kopf Instruments) at a frequency of 0.0167 Hz. In all experiments, a stimulus intensity that evoked an EPSP with 50% of the maximal slope was
used. The fEPSP slopes obtained during 15–20 minutes of stable baseline recording were averaged and then used to normalize fEPSP slopes
during drug application and washout to combine data from different
brain slices. EPSCs were recorded in voltage-clamp configuration from
individual CA1 pyramidal neurons in hippocampal slices prepared as
above from P21–P28 male CD-1 mice. Neurons were identified by infrared differential interference contrast videomicroscopy (52). The ACSF
was slightly modified for whole-cell recording in slices to contain 2 mM
CaCl2 and 1 mM MgCl2. NMDAR-mediated EPSCs were isolated by adding 10 μM NBQX. Patch electrodes for slice recording were filled with an
internal solution containing 140 mM potassium gluconate, 5 mM NaCl,
1 mM CaCl2, 2 mM MgATP, 10 mM EGTA, and 10 mM HEPES (pH 7.3).
Whole-cell recording from hippocampal neuron cultures were performed
by using an internal solution containing mM 140 mM potassium gluconate, 4 mM NaCl, 0.5 mM CaCl2, 2 mM MgATP, 0.5 mM Na2GTP, 5 mM
EGTA, and 10 mM HEPES (pH 7.2) and an external solution containing
140 mM NaCl, 5 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 10 mM HEPES,
and 10 mM glucose (pH 7.3). Analog data were obtained with an Axopatch 200B amplifier, digitized at 10 kHz, and analyzed with an Axon
Instruments Digidata 1322A and pClamp9 (Molecular Devices).
Statistics. All data are presented as the mean ± SD. Statistical analyses
were performed by using paired or unpaired 2-tailed t tests with appropriate corrections as indicated; ANOVA followed by Tukey-Kramer’s or
Kruskal-Wallis with Dunn’s post test were used for comparisons between
multiple groups. Statistical significance was set at P < 0.05.
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